ProCE Banner Activity

Novel Therapies, Improving Adherence, and Reducing Disparities in Psoriasis Care

Clinical Thought

This expert commentary reviews strategies for incorporating new and emerging therapies, improving medication adherence, and addressing healthcare disparities for patients with moderate to severe psoriasis.

Released: September 16, 2022

Expiration: September 15, 2023

No longer available for credit.



Steven Feldman

Steven Feldman, MD, PhD

Professor of Dermatology, Pathology and Social Sciences & Health Policy
Wake Forest University School of Medicine
Winston-Salem, North Carolina

Provided by

ProCE Banner
ProCE Banner


Supported by an educational grant from Novartis Pharmaceuticals Corporation.

Novartis Pharmaceuticals Corporation

Target Audience

Dermatologists and APPs and nurses who practice in dermatology.


Steven Feldman, MD, PhD: consultant/speaker: AbbVie, Accordant, Almirall, Alvotech, Amgen, Arcutis, Arena, Argenx, Biocon, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Forte, Helsinn, Janssen, Leo, Lilly, Mylan, Novartis, Pfizer, Samsung, Sanofi, Sun Pharma, Union Chimique Belge (UCB), vTv Therapeutics, Voluntis; researcher: Galderma, Janssen, Lilly, Pfizer, Regeneron; stock/stock options: Sensal Health.



Additional Information

Program Medium

This program has been made available online.